Yusuke Sato

List of Publications by Year in descending order

81 papers	8,635 citations	101543 36 h-index	64796 79 g-index
82 all docs	82 docs citations	82 times ranked	14126 citing authors

#	Article	IF	Citations
1	Frequent pathway mutations of splicing machinery in myelodysplasia. Nature, 2011, 478, 64-69.	27.8	1,764
2	Integrated molecular analysis of clear-cell renal cell carcinoma. Nature Genetics, 2013, 45, 860-867.	21.4	955
3	Mutational landscape and clonal architecture in grade II and III gliomas. Nature Genetics, 2015, 47, 458-468.	21.4	729
4	Integrated molecular analysis of adult T cell leukemia/lymphoma. Nature Genetics, 2015, 47, 1304-1315.	21.4	659
5	Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature, 2019, 565, 312-317.	27.8	476
6	Dynamics of clonal evolution in myelodysplastic syndromes. Nature Genetics, 2017, 49, 204-212.	21.4	348
7	Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood, 2017, 129, 2347-2358.	1.4	268
8	A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. Journal of Controlled Release, 2012, 163, 267-276.	9.9	264
9	Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems. Advanced Drug Delivery Reviews, 2018, 128, 84-100.	13.7	215
10	Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. Journal of Controlled Release, 2015, 216, 149-157.	9.9	157
11	Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Nature Communications, 2018, 9, 3649.	12.8	140
12	A new adjuvant delivery system â€˜cyclic di-GMP/YSK05 liposomeâ€™ for cancer immunotherapy. Journal of Controlled Release, 2014, 184, 20-27.	9.9	130
13	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood, 2018, 131, 215-225.	1.4	124
14	Development of the iLiNP Device: Fine Tuning the Lipid Nanoparticle Size within 10 nm for Drug Delivery. ACS Omega, 2018, 3, 5044-5051.	3.5	124
15	Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo. Journal of Controlled Release, 2019, 295, 140-152.	9.9	104
16	Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood, 2016, 127, 596-604.	1.4	98
17	The Effect of Size and Charge of Lipid Nanoparticles Prepared by Microfluidic Mixing on Their Lymph Node Transitivity and Distribution. Molecular Pharmaceutics, 2020, 17, 944-953.	4.6	98
18	A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells. Journal of Controlled Release, 2016, 225, 183-191.	9.9	97

#	Article	IF	Citations
19	Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers. PLoS ONE, 2017, 12, e0187962.	2.5	96
20	Genomic landscape of liposarcoma. Oncotarget, 2015, 6, 42429-42444.	1.8	94
21	Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery. Journal of Controlled Release, 2016, 229, 48-57.	9.9	81
22	Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 463-471.	3.4	76
23	Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus. Journal of Controlled Release, 2017, 266, 216-225.	9.9	73
24	A Neutral Envelopeâ€Type Nanoparticle Containing pHâ€Responsive and SSâ€Cleavable Lipidâ€Like Material as a Carrier for Plasmid DNA. Advanced Healthcare Materials, 2013, 2, 1120-1125.	7.6	67
25	Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy. Journal of Controlled Release, 2020, 325, 235-248.	9.9	65
26	Gene expression and risk of leukemic transformation in myelodysplasia. Blood, 2017, 130, 2642-2653.	1.4	64
27	Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines. Scientific Reports, 2016, 6, 37849.	3.3	60
28	Relationship Between the Physicochemical Properties of Lipid Nanoparticles and the Quality of siRNA Delivery to Liver Cells. Molecular Therapy, 2016, 24, 788-795.	8.2	59
29	Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection. Journal of Hepatology, 2016, 64, 547-555.	3.7	57
30	Lipid nanoparticles loaded with ribonucleoproteinâ€“oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition. Journal of Controlled Release, 2021, 330, 61-71.	9.9	54
31	Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors. International Journal of Pharmaceutics, 2016, 509, 178-187.	5.2	49
32	Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core. Molecular Pharmaceutics, 2018, 15, 2142-2150.	4.6	49
33	Multifunctional envelope-type nano device for controlled intracellular trafficking and selective targeting in vivo. Journal of Controlled Release, 2014, 190, 593-606.	9.9	48
34	In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus.. Scientific Reports, 2014, 4, 4750.	3.3	47
35	Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor. Journal of the National Cancer Institute, 2017, 109, .	6.3	43
36	The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy. Scientific Reports, 2019, 9, 11335.	3.3	42

#	Article	IF	Citations
37	Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines. Advanced Drug Delivery Reviews, 2022, 188, 114417.	13.7	42
38	Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E/low density lipoprotein receptor and the N-acetyl-d-galactosamine/asialoglycoprotein receptor pathway. Journal of Controlled Release, 2020, 322, 217-226.	9.9	40
39	Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting. International Journal of Nanomedicine, 2018, Volume 13, 8395-8410.	6.7	38
40	Innovative nanotechnologies for enhancing nucleic acids/gene therapy: Controlling intracellular trafficking to targeted biodistribution. Biomaterials, 2019, 218, 119329.	11.4	37
41	A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes. Journal of Controlled Release, 2019, 307, 55-63.	9.9	35
42	Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles. Acta Biomaterialia, 2020, 102, 341-350.	8.3	35
43	The use of design of experiments with multiple responses to determine optimal formulations for in vivo hepatic mRNA delivery. Journal of Controlled Release, 2020, 327, 467-476.	9.9	35
44	PEGylation of the GALA Peptide Enhances the Lung-Targeting Activity of Nanocarriers That Contain Encapsulated siRNA. Journal of Pharmaceutical Sciences, 2017, 106, 2420-2427.	3.3	32
45	Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA. Journal of Controlled Release, 2018, 284, 179-187.	9.9	32
46	pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes. Journal of Controlled Release, 2017, 262, 239-246.	9.9	31
47	Integrated Molecular Characterization of the Lethal Pediatric Cancer Pancreatoblastoma. Cancer Research, 2018, 78, 865-876.	0.9	25
48	The nanomedicine rush: New strategies for unmet medical needs based on innovative nano DDS. Journal of Controlled Release, 2021, 330, 305-316.	9.9	24
49	Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier. International Journal of Pharmaceutics, 2015, 495, 171-178.	5.2	23
50	Evolution of drug delivery system from viewpoint of controlled intracellular trafficking and selective tissue targeting toward future nanomedicine. Journal of Controlled Release, 2020, 327, 533-545.	9.9	23
51	Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis. Oncotarget, 2017, 8, 107513-107529.	1.8	23
52	Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer. Oncotarget, 2017, 8, 18657-18669.	1.8	21
53	Three-dimensional, symmetrically assembled microfluidic device for lipid nanoparticle production. RSC Advances, 2021, 11, 1430-1439.	3.6	18
54	On the size-regulation of RNA-loaded lipid nanoparticles synthesized by microfluidic device. Journal of Controlled Release, 2022, 348, 648-659.	9.9	18

#	Article	IF	Citations
55	Genome-Wide Analysis of Ocular Adnexal Lymphoproliferative Disorders Using High-Resolution Single Nucleotide Polymorphism Array. , 2015, 56, 4156.		17
56	Novel PEGylated Lipid Nanoparticles Have a High Encapsulation Efficiency and Effectively Deliver MRTF-B siRNA in Conjunctival Fibroblasts. Pharmaceutics, 2021, 13, 382.	4.5	17
57	The hydrophobic tail of a pH-sensitive cationic lipid influences siRNA transfection activity and toxicity in human NK cell lines. International Journal of Pharmaceutics, 2021, 609, 121140.	5.2	17
58	Lipid nanoparticles fuse with cell membranes of immune cells at low temperatures leading to the loss of transfection activity. International Journal of Pharmaceutics, 2020, 587, 119652.	5.2	16
59	Recent advances in the targeting of systemically administered non-viral gene delivery systems. Expert Opinion on Drug Delivery, 2019, 16, 1037-1050.	5.0	15
60	Development of Lipid Nanoparticles for the Delivery of Macromolecules Based on the Molecular Design of pH-Sensitive Cationic Lipids. Chemical and Pharmaceutical Bulletin, 2021, 69, 1141-1159.	1.3	14
61	Interferon signaling suppresses the unfolded protein response and induces cell death in hepatocytes accumulating hepatitis B surface antigen. PLoS Pathogens, 2021, 17, e1009228.	4.7	13
62	Combined nano cancer immunotherapy based on immune status in a tumor microenvironment. Journal of Controlled Release, 2022, 345, 200-213.	9.9	13
63	Genomic analysis of clonal origin of Langerhans cell histiocytosis following acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 175, 169-172.	2.5	12
64	Adults with germline CBL mutation complicated with juvenile myelomonocytic leukemia at infancy. Journal of Human Genetics, 2016, 61, 523-526.	2.3	12
65	Truncation and microdeletion of EVC/EVC2 with missense mutation of EFCAB7 in Ellisâ€van Creveld syndrome. Congenital Anomalies (discontinued), 2016, 56, 209-216.	0.6	9
66	Classification of clear cell renal cell carcinoma based on PKM alternative splicing. Heliyon, 2020, 6, e03440.	3.2	9
67	Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers. Cancers, 2021, 13, 348.	3.7	8
68	Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning. IScience, 2021, 24, 102722.	4.1	8
69	New Design Strategies for Controlling the Rate of Hydrophobic Drug Release from Nanoemulsions in Blood Circulation. Molecular Pharmaceutics, 2020, 17, 3773-3782.	4.6	6
70	Comprehensive Analysis of Aberrant RNA Splicing in Myelodysplastic Syndromes. Blood, 2014, 124, 826-826.	1.4	6
71	Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody. International Journal of Pharmaceutics, 2022, 624, 122034.	5.2	6
72	Maximizing the Oral Bioavailability of Poorly Water-Soluble Drugs Using Novel Oil-Like Materials in Lipid-Based Formulations. Molecular Pharmaceutics, 2021, 18, 3281-3289.	4.6	5

#	Article	IF	Citations
73	Chronological Analysis of Clonal Evolution in Acquired Aplastic Anemia. Blood, 2014, 124, 253-253.	1.4	4
74	In Analogy to AML, MDS Can be Sub-Classified By Ancestral Mutations. Blood, 2014, 124, 823-823.	1.4	4
75	Two Modes of Toxicity of Lipid Nanoparticles Containing a pH-Sensitive Cationic Lipid on Human A375 and A375-SM Melanoma Cell Lines. BPB Reports, 2019, 2, 48-55.	0.3	3
76	Innovative cancer nanomedicine based on immunology, gene editing, intracellular trafficking control. Journal of Controlled Release, 2022, 348, 357-369.	9.9	3
77	Retrograde Axonal Transport of Liposomes from Peripheral Tissue to Spinal Cord and DRGs by Optimized Phospholipid and CTB Modification. International Journal of Molecular Sciences, 2022, 23, 6661.	4.1	2
78	Partial monosomy of 10p and duplication of another chromosome in two patients. Pediatrics International, 2017, 59, 99-102.	0.5	1
79	Landscape of Genetic Alterations in Adult T-Cell Leukemia/Lymphoma. Blood, 2014, 124, 75-75.	1.4	1
80	The landscape and clonal architecture in lower grade glioma.. Journal of Clinical Oncology, 2015, 33, 2008-2008.	1.6	0
81	Novel and Significant Impact of Germline Variants Predisposed to Pathogenic Somatic Mutations and Loss of Heterozygosity (LOH) in Myelodysplastic Syndromes (MDS) and Clonal Hematopoiesis of Indeterminate Potential (CHIP). Blood, 2018, 132, 108-108.	1.4	0